| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| 10g | |||
| Other Sizes |
| Targets |
TBMP targets the viral envelope protein hemagglutinin (HA), inhibiting HA-mediated viral entry. It is a PROTAC linker. It induces increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of mice, regulating the carcinogen metabolism system.
|
|---|---|
| ln Vitro |
In vitro, TBMP exhibits significant antioxidant activity as a DPPH radical scavenger with an IC50 of 9.3 μg/mL. It induces increased activities of glutathione (GSH) S-transferase and epoxide hydrolase. It has insecticidal activity and inhibits HA-mediated viral entry.
|
| ln Vivo |
In vivo, TBMP induces increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of A/HeJ mice, regulating the carcinogen metabolism system. It has insecticidal activity. The compound is used as a PROTAC linker in research applications.
|
| Enzyme Assay |
In vitro enzyme assays for TBMP measure its antioxidant activity using DPPH radical scavenging assays, with an IC50 of 9.3 μg/mL. The compound's ability to induce GSH S-transferase and epoxide hydrolase activities is assessed in liver and forestomach tissue homogenates. Inhibition of HA-mediated viral entry is measured in cell-based viral entry assays.
|
| Cell Assay |
In vitro cell-based assays for TBMP assess its effects on viral entry and enzyme induction. Cells are treated with serial dilutions of the compound, and HA-mediated viral entry is measured. GSH S-transferase and epoxide hydrolase activities are measured in cell lysates. Cell viability is assessed in parallel.
|
| Animal Protocol |
In vivo animal models for TBMP include A/HeJ mice treated with the compound to assess effects on GSH S-transferase and epoxide hydrolase activities in liver and forestomach tissues. Insecticidal activity is assessed in insect models. The compound is administered orally or via other routes.
|
| ADME/Pharmacokinetics |
TBMP has a molecular formula of C₁₁H₁₆O₂ and a molecular weight of 180.24 g/mol. It is also known as 3-tert-Butyl-4-methoxyphenol and butylated hydroxyanisole. It is a PROTAC linker belonging to the alkyl/ether class. It is stored under appropriate conditions for research use.
|
| Toxicity/Toxicokinetics |
TBMP has a favorable safety profile at research concentrations. It induces enzyme activities involved in carcinogen metabolism. The compound is for research use only and is not approved for clinical use. Appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
2-tert-butyl-4-hydroxyanisole is an aromatic ether, a derivative of 4-methoxyphenol, in which a hydrogen atom at the ortho position of the methoxy group is replaced by a tert-butyl group. It belongs to the phenolic class and is also an aromatic ether.
TBMP (3-tert-Butyl-4-methoxyphenol, butylated hydroxyanisole) is a PROTAC linker with insecticidal activity. It inhibits viral envelope protein hemagglutinin (HA)-mediated entry. TBMP exhibits significant antioxidant activity as a DPPH radical scavenger with an IC50 of 9.3 μg/mL. It induces GSH S-transferase and epoxide hydrolase activities in mouse tissues. |
| Exact Mass |
180.115
|
|---|---|
| CAS # |
88-32-4
|
| PubChem CID |
6932
|
| Appearance |
White to off-white solid powder
|
| Density |
1.009 g/cm3
|
| Boiling Point |
293.3ºC at 760 mmHg
|
| Melting Point |
64℃
|
| Flash Point |
136ºC
|
| Index of Refraction |
1.507
|
| LogP |
2.698
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
160
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=C(C(C)(C)C)C(OC)=CC=1
|
| InChi Key |
IMOYOUMVYICGCA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H16O2/c1-11(2,3)9-7-8(12)5-6-10(9)13-4/h5-7,12H,1-4H3
|
| Chemical Name |
3-tert-butyl-4-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
